Direct Peptide Sales

Reference data

Peptide and GLP-1 regulations by state

A single table that answers the questions clinics ask before launching in a new state: who regulates it, what permit the pharmacy needs, which telehealth rule applies, and what the first visit has to look like. Each row links to a fuller state page with primary citations.

Direct Peptide Sales is a referral service for licensed practices and wellness businesses. We introduce you to licensed prescribers and 503A/503B pharmacies. We do not sell, prescribe, bill, or ship product.

Last reviewed · Editorial policy

How to read the matrix

Columns are chosen to match the diligence checklist most practices run.

  • Regulatory bodies: the pharmacy and medical boards that hear complaints and set rules
  • 503B non-resident requirement: the permit an out-of-state outsourcing facility needs before shipping office-use stock in
  • Telehealth authority: the statute or board rule that governs a remote prescriber-patient relationship
  • First-prescription visit standard: whether a video visit is expected before the first peptide or GLP-1 prescription
  • Interstate compact: whether the state accepts the Interstate Medical Licensure Compact, where the source states it

Patterns worth noticing

Three things repeat across the table. Nearly every state expects a synchronous video visit before a first prescription, with asynchronous refills allowed under a documented care plan. Every state requires the shipping pharmacy to hold its own non-resident permit, so the pharmacy's license list matters as much as the prescriber's. And the states with the most program growth, Florida and Texas, are also the ones with the most active board advisories on compounded GLP-1 marketing.

Frequently asked questions

What does this state matrix cover?
For each state it lists the regulatory bodies, the non-resident permit a 503B outsourcing facility needs to ship in, the telehealth statute or rule that governs prescribing, the visit standard for a first peptide or GLP-1 prescription, interstate compact status where stated, and a short enforcement note.
Where does the data come from?
Each row summarizes public statutes, board rules, and board advisories that are cited on the matching state compliance page. The matrix is a condensed view of those notes, not additional research, and it is not legal advice.
Why are only some states listed?
Only states with a fully cited compliance page are included in the matrix. States are added as their pages are reviewed, and the review date is shown on this page.
Can I download or reuse the table?
Yes. The CSV export is free to download and cite with attribution to Direct Peptide Sales and a link to this page.
Does Direct Peptide Sales sell peptides in these states?
No. We do not sell, ship, or hold product. We verify licensed practices and introduce them to telehealth prescribers and 503A or 503B pharmacy sources that hold the right permits for their states.
What exactly does Direct Peptide Sales do?
We are a referral and introduction service. We verify your business and the states it serves, then introduce you to licensed telehealth prescribers and 503A or 503B pharmacies. You contract directly with them. We do not sell, price, prescribe, compound, bill, or ship any product.
How fast can my practice be introduced to a source?
Most qualified practices receive an introduction within one business day of applying. How quickly you go live after that depends on the agreement you sign with the prescriber and pharmacy you choose.
What does it cost?
Nothing to apply, and we do not charge practices a fee. Product pricing, account terms, and any minimums are set by the pharmacy or prescriber you contract with, not by us.
Where do the peptides come from and are they verified?
Product comes from the licensed US 503A and 503B pharmacies you contract with. We only introduce sources that issue independent per-lot Certificates of Analysis covering identity, purity, sterility, and endotoxin. You can review sample COAs on this site before you apply.
Who handles prescribing, billing, and shipping?
The licensed prescriber and the pharmacy do. Prescribing is the provider's independent clinical decision, and dispensing, billing, and shipping sit with the pharmacy. We are not part of that transaction.
What if I'm not a licensed clinic?
Non-licensed wellness businesses such as coaches, gyms, studios, and nutrition practices can be introduced to a licensed telehealth prescriber who owns the clinical relationship. You never prescribe, hold, or dispense product.
How do you vet the sources you introduce?
Every source must be a named 503A pharmacy or FDA-registered 503B outsourcing facility, hold non-resident licensure in the states it ships into, issue per-lot Certificates of Analysis, and use prescribers licensed in the patient's state. We decline sources using research-use-only language.
Which states do you serve?
We make introductions across the United States and match you to partners that hold the right licensure for the states you serve.

State rules matrix

Download CSV

9 states. Reviewed 2026-09-02. Public-record summaries, not legal advice.

Peptide and GLP-1 Regulations by State (2026 Matrix)
StateRegulatory bodies503B non-resident requirementTelehealth authorityFirst-prescription visit standardInterstate compactEnforcement note
ArizonaBoard of Pharmacy; Medical Board; Naturopathic Physicians Medical BoardAZ Non-Resident Pharmacy PermitARS 36-3606Audio-video visit; async accepted for refills with care planIMLC acceptedPermissive for med spa programs; naturopaths hold prescriptive authority under ARS 32-1502
ColoradoState Board of Pharmacy; Colorado Medical BoardCO Non-Resident Prescription Drug Outlet RegistrationCRS 12-240-107Video or asynchronous under a documented planIMLC acceptedStandard enforcement, attentive to sterile compounding practice
FloridaBoard of Pharmacy; Board of Medicine (DOH)FL Non-Resident Sterile Compounding PermitFL Statute 456.47 (telehealth registration)Synchronous visit; async-only generally insufficientTelehealth registration routeHigh scrutiny of marketing claims and cash-pay structures; BOP advisories on compounded semaglutide sourcing
GeorgiaBoard of Pharmacy; Composite Medical BoardGA non-resident pharmacy licensureGCMB Rule 360-3-.07Video visit; audio-only typically insufficientNot statedIncreased board activity on cash-pay marketing through 2025
IllinoisIDFPR (Pharmacy and Medical)IDFPR 503B non-resident registrationIllinois Telehealth Act (225 ILCS 150)Video standard; audio-only permitted narrowlyNot statedRegular IDFPR review of GLP-1 compounding marketing and dispensing chain
NevadaState Board of Pharmacy; Board of Medical ExaminersNV non-resident permit (NRS 639); COA on requestNRS 629.515Video visit; async accepted for refills with plan of careIMLC acceptedActive BOP enforcement on marketing and chain of custody
New YorkNYSED Office of the Professions; DOH Bureau of Pharmacy; BNENY Non-Resident Establishment registrationPublic Health Law 2999-ccEstablished relationship; async-only risky for first RxIMLC not acceptedState-level USP 797 equivalent plus extra sterile compounding recordkeeping
TennesseeBoard of Pharmacy; Board of Medical ExaminersTN non-resident permitTCA 63-6-209Video visit for first Rx; async refills with care planInterstate compact license acceptedBoard guidance on GLP-1 compounding oversight issued 2024-2025
TexasState Board of Pharmacy; Texas Medical BoardTX Non-Resident Class E Pharmacy licenseOccupations Code Ch. 111; TMB Rule 174Video visit; audio-only alone typically insufficientNot statedTMB advisories on GLP-1 compounding and marketing; frequent TSBP audits

Cite as: Direct Peptide Sales, "Peptide and GLP-1 Regulations by State (2026 Matrix)", https://directpeptidesales.com/peptide-regulations-by-state. Licensed CC BY 4.0.

Get introduced to sources licensed for your states

Tell us the states your patients live in and we will introduce prescribers and 503A/503B pharmacies that already hold the right permits.

Get Started

Related programs